Clinical trials: COPD Patients
Pulmonary Disease, Chronic Obstructive
Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease
GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00515502
- Testing
- GSK573719, Tiotropium
- Where
- 3 sites in Germany
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
QVA Mechanistic Efficacy Study (Receptor Effects, Etc)
The purpose of this study was to assess global ventilated lung volume in moderate to severe COPD patients using MRI lung imaging after treatment with QVA149 compared to placebo.
- Trial name
- NCT02634983
- Testing
- QVA149
- Where
- 3 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)
The primary objective of this Non Interventional Study is to measure changes in physical functioning, a surrogate for physical activity and exercise capacity, in COPD patients on treatment with Spiolto® Respimat® in routine daily…
- Trial name
- NCT02720757
- Testing
- Spiolto Respimat
- Where
- 6 sites in Belgium, Denmark and 4 more
- Volunteers
- 132 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in Chronic Obstructive Pulmonary Disease (COPD) patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end…
- Trial name
- NCT01040728
- Testing
- Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg
- Where
- 12 sites in United States, Germany and 2 more
- Volunteers
- 122 people
- Sponsor
- Boehringer Ingelheim
COPD Patients
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
Comparing the efficacy of Symbicort® pMDI and Formoterol Turbuhaler in reducing exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- RISE (NCT02157935)
- Testing
- Symbicort, Formoterol turbohaler
- Where
- 371 sites in United States, Argentina and 9 more
- Volunteers
- 2,026 people
- Sponsor
- AstraZeneca
COPD, Sepsis
Effect of Nebulized Bronchodilators on Heart Rate
The purpose of the study is to determine adverse events rates of nebulized albuterol versus levalbuterol among adult critically ill patients and determine if a differential exists in adverse events between the two drugs.
- Conditions
- COPD, Sepsis, Shock
- Trial name
- NCT01151579
- Testing
- Levalbuterol, Albuterol
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Fahim Khorfan, MD
Pulmonary Disease, Chronic Obstructive, Obesity
INtervention Study In overweiGHT Patients With COPD
Symptoms of chronic obstructive pulmonary disease (COPD) and high body mass index (BMI) overlap. The investigators are trying to find out if a program proven to help people lose a modest amount of weight and increase their…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Obesity, Weight Loss, Life Style
- Trial name
- INSIGHT COPD (NCT02634268)
- Testing
- Lifestyle Intervention
- Where
- 39 sites in United States
- Volunteers
- 684 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate
The purpose of this multicenter, dose-ranging study is to compare two Fixed-Dose Combinations of aclidinium bromide and formoterol fumarate with placebo, aclidinium bromide and formoterol fumarate, all administered BID in…
- Trial name
- ALIGHT-COPD (NCT01078623)
- Testing
- Aclidinium 200 μg / formoterol 12 μg, Formoterol 12 μg, Aclidinium 200 μg
- Where
- 10 sites in Czechia, Romania
- Volunteers
- 176 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy
The purpose of the study is to measure changes in physical functioning in chronic obstructive pulmonary disease (COPD) patients being treated with Spiolto® Respimat® after approximately 6 weeks in routine clinical practice.
- Trial name
- OTIVACTO (NCT03003494)
- Testing
- Spiolto® Respimat®
- Where
- 28 sites in Italy
- Volunteers
- 306 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Effect of Ketoconazole on Breathlessness
Beta-endorphins, which are naturally occurring narcotic substances, have been shown to alter the perception of breathlessness. Oral ketoconazole, an antifungal antibiotic, increases blood levels of beta-endorphins.
- Trial name
- KetoRLB (NCT01378520)
- Testing
- ketoconazole, inert powder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Early Warning System
The study will begin in 2013 whereby patients having an early warning system (EWS) alert will be randomized to be seen by the rapid response team (RRT) for triage versus usual care.
- Conditions
- Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cancer, Diabetes Mellitus
- Trial name
- NCT01741480
- Testing
- Early warning system monitoring., routine care
- Where
- United States
- Volunteers
- 571 people
- Sponsor
- Washington University School of Medicine
Pulmonary Disease, Chronic Obstructive
Benefits of Lightweight Ambulatory Oxygen Systems for Individuals With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) affects over 14 million people in the United States. It is the fourth leading cause of death and the only leading cause of death for which mortality rates are rising.
- Trial name
- NCT00325754
- Testing
- E-Cylinder, Lightweight Cylinder
- Where
- 10 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of Minnesota
Pulmonary Disease, Chronic Obstructive, Lung Diseases
A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease
PF-03635659 is being developed for the treatment of chronic obstructive pulmonary disease. This is a study to examine the safety, pharmacokinetics and pharmacodynamics of PF-03635659 in patients with Chronic Obstructive Pulmonary…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Respiratory Tract Diseases, Chronic Obstructive Airway Disease
- Trial name
- NCT01033487
- Testing
- active comparator, Low Dose PF-03635659, Mid Dose PF-03635659
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Supplemental Vitamin D on Skeletal Muscle Function in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to determine whether or not vitamin D supplementation can improve physical performance in persons with severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00914810
- Testing
- Vitamin D (cholecalciferol)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Chronic Obstructive Pulmonary Disease
Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD
Our primary hypothesis is that Roflumilast (500 μcg, once daily) will significantly decrease surrogate markers of bone metabolism and early cardiovascular disease in individuals with moderate to severe airflow obstruction and a…
- Trial name
- NCT01745848
- Testing
- Roflumilast
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Pittsburgh
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary purpose of the study is to investigate if Symbicort is more effective than Oxis in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in patients with COPD.
- Trial name
- SUMIRE (NCT01069289)
- Testing
- Budesonide/formoterol (Symbicort Turbuhaler), Formoterol (Oxis Turbuhaler)
- Where
- 119 sites in India, Japan and 7 more
- Volunteers
- 1,293 people
- Sponsor
- AstraZeneca
COPD, Chronic Bronchitis
The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis
Specific Aim: To determine the effectiveness of Roflumilast in improving i) whole right lung and ii) peripheral right lung mucociliary clearance (MCC) in patients with COPD and chronic bronchitis.
- Conditions
- COPD, Chronic Bronchitis, Emphysema
- Trial name
- NCT03073798
- Testing
- Roflumilast
- Volunteers
- 12 people
- Sponsor
- Johns Hopkins University
Pulmonary Disease, Chronic Obstructive, Emphysema
Sildenafil for Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine if sildenafil improves the exercise capacity and lung function of patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00104637
- Testing
- sildenafil citrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Kawut, Steven, MD
COPD, Dyspnea
Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients
Dyspnea is the most common symptom limiting the ability of COPD patients to perform activities of daily living. Although there has been research involving the benefit of providing Non Invasive Ventilation (NIV) during exercise to…
- Trial name
- NCT03349437
- Testing
- Vitabreath Device, Pursed Lip Breathing
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Philips Respironics
Chronic Obstructive Pulmonary Disease
Exacerbation Study
This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks
- Trial name
- INVIGORATE (NCT00845728)
- Testing
- Indacaterol 150 µg, Tiotropium
- Where
- 423 sites in Argentina, Australia and 38 more
- Volunteers
- 3,439 people
- Sponsor
- Novartis Pharmaceuticals